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ABSTRACT: Guineensine is a dietary N-isobutylamide widely present in black and long pepper (Piper nigrum and Piper longum)
previously shown to inhibit cellular endocannabinoid uptake. Given the role of endocannabinoids in inﬂammation and pain
reduction, here we evaluated guineensine in mouse models of acute and inﬂammatory pain and endotoxemia. Signiﬁcant dose-
dependent anti-inﬂammatory eﬀects (95.6 ± 3.1% inhibition of inﬂammatory pain at 2.5 mg/kg ip and 50.0 ± 15.9% inhibition of
edema formation at 5 mg/kg ip) and acute analgesia (66.1 ± 28.1% inhibition at 5.0 mg/kg ip) were observed. Moreover,
guineensine inhibited proinﬂammatory cytokine production in endotoxemia. Intriguingly, guineensine and LPS independently
induced catalepsy, but in combination this eﬀect was abolished. Both hypothermia and analgesia were blocked by the CB1
receptor inverse agonist rimonabant, but the pronounced hypolocomotion was CB1 receptor-independent. A subsequent screen
of 45 CNS-related receptors, ion channels, and transporters revealed apparent interactions of guineensine with the dopamine
transporter DAT, 5HT2A, and sigma receptors, uncovering its prospective polypharmacology. The described potent
pharmacological eﬀects of guineensine might relate to the reported anti-inﬂammatory eﬀects of pepper.
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■ INTRODUCTION
Guineensine belongs to a class of unique natural N-
isobutylamides bearing a benzodioxane moiety terminal to the
alkyl chain and was ﬁrst isolated fromWest African pepper (Piper
guineense Schumach).1 This fatty acid derived natural product is
abundant in several species of the plant genus Piper, including the
dietary pepper species P. longum L. and P. nigrum L.,2 where it is
present in about 0.5% of the dry weight in the fruits.3 Black
pepper is one of the most popular spices worldwide and
extensively employed for its culinary (i.e., spicy) but also medical
properties.4 Pepper is known to contain diﬀerent bioactive
phytochemicals such as the major alkaloids piperin and its isomer
chavicin,4 which exert numerous biological eﬀects, including
activation of TRP and K2P channels5 which mediate the
pungency of piperin. However, relatively little is known about the
biological eﬀects of the abundant Piper N-alkylamides. The
outstanding bioactivity of guineensine (Figure 1) in vivowas only
recently reported.6 Although guineensine has been shown to be
insecticidal,7 signiﬁcant to moderate noteworthy eﬀects on
mammalian targets have been reported too. For instance,
guineensine was shown to inhibit the Acyl-CoA cholesterol
acyltransferase (IC50 = 3.12 μM)
8 and alpha glucosidase-I (IC50 =
19.2 μg/mL).3 Themost potent biological activity of guineensine
reported relates to its inhibition of the endocannabinoid uptake
process, with an IC50 = 290 nM for anandamide (AEA) in U937
cells.6 This mechanism was matched by indirect activation of
cannabinoid CB1 receptors and overall cannabimimetic eﬀects in
mice.6 Interestingly, the natural N-alkylamide N-benzyl-
(9Z,12Z)-octadecadienamide from Peruvian Maca (Lepidium
meyeniiWalp.) was shown to likewise inhibit anandamide uptake
(IC50 = 670 nM).
9 Diﬀerent natural and synthetic N-alkylamides
have been identiﬁed as potential modulators of endocannabinoid
transport, and Chicca and Nicolussi et al. (2017) recently
reported the ﬁrst potent and selective endocannabinoid cellular
reuptake inhibitor, WOBE437, which was derived from the
natural 2,4-dodecadienamide scaﬀold from coneﬂower (Echina-
cea spp.).10 Altogether, this strongly suggests that structural
similarities between endocannabinoids and N-alkylamides from
plants can cause noteworthy biological activities within the
endocannabinoid system (ECS). Only N-alkylamides that are
not substrates of serine hydrolases like fatty acid amide hydrolase
(FAAH) can exert central pharmacological eﬀects in vivo. It was
previously shown that guineensine is not metabolized by FAAH
or any of the known serine hydrolases involved in the ECS, but
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Figure 1. Chemical structure of guineensine ((2E,4E,12E)-13-(1,3-
benzodioxol-5-yl)-N-(2-methylpropyl)trideca-2,4,12-trienamide).
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exhibits central cannabimimetic eﬀects in mice,6 namely,
hypothermia, catalepsy, hypolocomotion, and analgesia (collec-
tively referred to as tetrad), typically observed upon activation of
central CB1 receptors.11 The indirect cannabinoid receptor
activation by guineensine is assumed to be related to its
inhibition of central reuptake of the major endocannabinoids
AEA and 2-arachidonoylglycerol (2-AG), similar to the synthetic
endocannabinoid reuptake inhibitor WOBE437, which is more
selective and more potent.10
CB1 receptors, which mediate retrograde signaling leading to
the inhibition of synaptic circuits at both glutamatergic and
GABAergic synapses, are abundantly expressed in the CNS and
have been associated with analgesia, but also immunomodula-
tion.12 In our previous study, the analgesic eﬀect of guineensine
measured in the hot plate assay could be inhibited by the CB1
antagonist/inverse agonist rimonabant, while the eﬀects on body
temperature and locomotion were only partially blocked.6
Endocannabinoids also interact with other proteins, including
ion channels and nuclear receptors involved in immunomodu-
lation.13 Moreover, the ECS is involved in regulating numerous
biochemical processes related to cellular stress and homeostasis,
and it modulates also fundamental pathophysiological processes,
including inﬂammation and pain.13
Given the emerging link between nutrition and the ECS,14
here we studied the anti-inﬂammatory and analgesic eﬀects of
guineensine, the most potent natural endocannabinoid uptake
inhibitor reported so far, in diﬀerent mouse models of
inﬂammation. To our knowledge, guineensine has not previously
been studied in the context of inﬂammation despite the reported
anti-inﬂammatory and analgesic eﬀects of black pepper.4 In our
previous study, guineensine induced signiﬁcant hypolocomotion
under basal physiological condition that could only partially be
inhibited by CB1 receptor antagonism.6 Therefore, we proﬁled
guineensine in vitro in a screening panel of 45 receptors, ion
channels, and transporters related to CNS pharmacology, with
the aim to further explore its potential polypharmacology. Our
data show that upon intraperitoneal administration, guineensine
exerts signiﬁcant anti-inﬂammatory eﬀects in diﬀerent mouse
models, including endotoxemia. Moreover, we propose addi-
tional CNS targets for this dietary natural product which may
explain, at least in part, the CB1 receptor-independent
extrapyramidal eﬀects.
■ MATERIALS AND METHODS
Chemicals. Guineensine (≥95% pure in HPLC) was isolated and
puriﬁed as previously described.6 Formalin, indomethacin (Indo), and
dimethyl sulfoxide (DMSO) puriss. and sterile ﬁltered were obtained
from Sigma-Aldrich (St. Louis, MO). Rimonabant (≥98% pure) was
obtained from pharmaserv AG (Stansstad, Switzerland).
Materials. Lipopolysaccharide (LPS; Escherichia coli, serotype
O55:B5) and carrageenan were obtained from Sigma-Aldrich (St.
Louis, MO). Bio-Plex ProMouse Chemokine assays were obtained from
Bio-Rad (Hercules, CA).
Animals. Male BALB/c mice (8 to 10 weeks old; 20−25 g body
weight) were supplied by the Centro de Investigacioń Biomed́ica de
OccidenteInstituto Mexicano del Seguro Social and kept under
standard environmental conditions (24 ± 2 °C; light−dark cycle of
12:12 h) with food and water ad libitum. Mice were handled according to
Mexican Federal Regulations for the Care and Use of Laboratory
Animals NOM-062-ZOO-1999 (Mexican Ministry of Health), which is
in accordance with the Code of Ethics of the Directive 2010/63/EU. For
all the experiments, guineensine, rimonabant, or vehicle (DMSO) was
administered intraperitoneally (ip) in a volume of 20 μL. At the vehicle
dose used (1 mL/kg) no signiﬁcant eﬀects on the disease models were
observed.
Formalin Test. Formalin provokes a biphasic painful behavior when
it is administered intraplantarly. The ﬁrst phase lasts 0 to 10 min after
injection, and then, after a quiescent period, the second phase lasts 15 to
60 min.15 The test was carried out individually with a BALB/c male
mouse in a Plexiglas cage (20 × 20 cm). After a habituation period of 5
min, formalin was injected in the right hind paw (20 μL at 1% formalin in
saline solution). Immediately, mice were gently placed in the cage and
paw shaking was recorded during 60min. Paw shaking was counted for 1
min every 5 min, and data were analyzed as percentage per phase.
Carrageenan-Induced Paw Edema. Paw inﬂammation was
induced in BALB/c male mice by subplantar administration of 1%
carrageenan in saline solution (w/v, 50 μL) into the right hind paw. Paw
thickness was measured with a digital micrometer (Mitutoyo; Takatsu-
ku, Japan) immediately prior to the injection of carrageenan (T0) and
thereafter at every 30 min for 3 h after carrageenan injection.
Inﬂammation was evaluated as the increase in paw thickness (edema)
at every time point (TX) relative toT0 and was reported in percentage. In
addition, hyperalgesia was evaluated by mechanical sensitivity, with a
digital algometer (Bioseb; Pinellas Park, FL) at T0 and 4 h after
carrageenan injection. The pain threshold was reported as percentage
relative to T0.
LPS-Induced Hypothermia. When high doses of LPS (2−5 mg/
kg) are injected into mice, this leads to an inﬂammatory reaction with
cytokine release and hypothermia.16 For this, BALB/c male mice were
injected ip, always in the evening (2−5 pm), with 2.5 mg/kg of LPS in
saline. Rectal temperature was measured with a thermocouple probe
(Physitemp Instruments; Clifton, NJ) right before LPS injection (T0)
and at every 30 min (TX) for 2 h. Data were expressed as temperature
change for each time point (TX − T0), and the area under the curve was
calculated with the GraphPad Prism software version 6.
Open Field Test. Motor changes after LPS-induced hypothermia
were evaluated in an open ﬁeld box (40 × 40 × 30 cm, Plexiglas). The
mice were individually placed in the center and allowed to move freely
for 5 min. The locomotion activity was recorded with the Open-
FieldTest (programed by Mario Coutiño), and the active time and
distance were evaluated automatically. After every experiment, the box
was cleaned with 70% ethanol to remove odors.
Cytokine Serum Levels.Mice were sacriﬁced by decapitation 2.5 h
after LPS injection, the blood was recovered immediately thereafter, and
serum was separated by centrifugation. IL1-β, TNF-α, and IL-6 were
measured with Bio-Plex Pro Mouse Chemokine assays (Bio-Rad;
Hercules, CA) and quantiﬁed with the MAGPIX Multiplex Reader
(Luminex; Austin, TX), according to the manufacturer’s instruction.
Tetrad Test. The tetrad test battery was conducted to evaluate the
central cannabimimetic eﬀect of guineensine upon LPS-induced
hypothermia. For this, guineensine or vehicle was administered ip 1 h
after LPS (2.5 mg/kg, ip) and the tetrad test battery was carried out 1 h
later, as previously described.10 In short, rectal temperature was
measured right before and 1 h post guineensine or vehicle injection, and
change in body temperature was expressed as the diﬀerence between
these temperatures. Catalepsy was measured using the bar test, where
the mouse was retained in an imposed position with forelimbs resting on
a bar of 4 cm height. Latency in this position was measured until both
front limbs were removed or remained over 120 s. Hypolocomotion was
determined using the rotarod test where the animals were trained to
walk under a rotarod (Erweka; Heusenstamm, Germany) at 4 rpm. For
the test, latency to fall was measured with a cutoﬀ time of 120 s.
Catalepsy and hypolocomotion were measured independently in three
trials. The hot plate tests were performed to evaluate analgesia, using a
54−56 °C hot plate (Thermo Scientiﬁc; Waltham, MA) with a Plexiglas
cylinder. Animals were gently placed in the plate, and latency to ﬁrst
nociceptive response (paw lick or foot shake) was measured.
Pretreatment with rimonabant (SR1) was used to evaluate CB1
antagonism. SR1 was administered ip 30 min before guineensine
injection.
In Vitro Pharmacological Screening. Guineensine was proﬁled in
more detail in an extended CNS adverse drug reaction screening panel
and tested for the interaction with the below indicated potential oﬀ-
target proteins (45); receptors, transporters, and ion channels expressed
in the CNS. The threshold to exclude a signiﬁcant interaction was set as
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a binding/response of >50%. CNS-expressed catalogue reference
number of each assay is indicated in parentheses referring to the
performed CEREP assay (www.cerep.com): a1A, adrenergic receptor
(2338); a2B, adrenergic receptor (1344); a2C, adrenergic receptor
(0016); BRS3, bombesin-receptor subtype 3 (BB3) (0472); CB1,
cannabinoid receptor type 1 (0036); CB2, cannabinoid receptor type 2
(0037); D1, dopamine receptor type 1 (0044); D2, dopamine receptor
type 2 (1322); D3, dopamine receptor type 3 (0048); D4.4, dopamine
receptor subtype 4.4 (0049); D5, dopamine receptor type 5 (0050);
GABAA BZD, GABAA channel at the benzodiazepine binding site
(0028); GABAA a1, β2, g2 site (3051); NMDA, NMDA (glutamate)
receptor subunit NR1 (0066); TNF-α (0076); H1, histamine receptor
type 1 (0870); MT3, melatonin receptor (ML2) (0088); MAO-A,
monoamine oxidase A (0443); M5, muscarinic receptor (0097); d2
(DOP) δ-type opioid receptor (0114); μ-type (MOP) opioid receptor
(0118); NMDA, PCP (0124); 5-HT1A serotonin receptor (0131); 5-
HT2A (0471); 5-HT2B (1333); 5-HT2C (1003); 5-HT3 (0411); 5-
HT4e (0501); 5-HT5a (0140); 5-HT6 (0142); 5-HT7 (0144); sigma
receptor (3500); AR, androgen receptor (0933); Na+ channel (site 2)
(0169); Cl− channel (GABA-gated) (0170); NAT, noradrenaline
transporter (0355); DAT, dopamine transporter (0052); GABA
transporter (0060); 5-HT transporter, serotonin transporter (0439);
AChE, acetylcholinesterase (0363); GABA TA, GABA transaminase
(0461); Tyr hydroxylase, tyrosine hydroxylase (0214); S1P1,
sphingosine receptor (3269); TRPV1, transient receptor potential
vanilloid 1 (1640); P-gp, P-glycoprotein (1324). All binding and
functional assays were performed as a single screen in duplicate and
guineensine was tested at the concentration of 10 μM.
Statistical Analyses. All data are presented as mean± SD and were
analyzed by nonparametrical approached with Kruskal−Wallis test
followed by Mann−Whitney U as a post hoc test. For time-course
analyses of carrageenan-induced paw edema and LPS-induced hypo-
thermia, data were analyzed by two-way ANOVA and Bonferroni post
test. A conﬁdence level of P < 0.05 was considered statistically
signiﬁcant. Analyses were carried out using the GraphPad Prism
software version v6.0 (La Jolla, CA).
■ RESULTS
Guineensine Decreased Nociceptive and Inﬂamma-
tory Pain in the Formalin Test in BALB/c Mice. The pain
behavior (paw shaking) observed in the ﬁrst phase of the
formalin test is due to nociceptor activation, but the second phase
starts with an acute inﬂammatory process (Figure 2A). 5.0 mg/kg
ip of guineensine was the dose necessary to signiﬁcantly reduce
paw shaking in both phases, with 66.1 ± 28.1 and 97.8 ± 3.7% of
pain inhibition per phase, respectively (Figures 2B and 2C). At a
dose of 10.0 mg/kg ip, paw shaking was inhibited by 26.0 ± 2.5
and 87.2 ± 8.2% in the ﬁrst and the second phase, respectively.
Thus, the eﬀect of guineensine was biphasic, which may be due to
its polypharmacology (see below). At the dose of 2.5 mg/kg ip
guineensine selectively but strongly reduced the inﬂammatory
pain by 95.6 ± 3.1% as measured by paw shaking (Figure 2C).
Carrageenan-Induced Edema in BALB/c Mice Was
Abolished by Guineensine. Carrageenan is a polysaccharide
that induces a strong inﬂammatory reaction when it is
administered via the intraplantar.17 In Figure 3A, the time
course of the edema formation (expressed as percentage of
inﬂammation) relative to basal condition is shown. Guineensine
at 5.0 mg/kg ip signiﬁcantly decreased the degree of edema
(inﬂammation) by approximately 50% between 30 and 90 min
after carrageenan injection (Figure 3A). This was also signiﬁcant
(50.0 ± 15.9% inhibition) when the total area under the curve
was analyzed as % edema formation (Figure 3B). In addition, the
Figure 2. Eﬀects of guineensine in male BALB/c mice on persistent pain in the formalin test. (A) Time course of paw shaking. (B) Percentage of pain
inhibition in phase 1. (C) Percentage of pain inhibition in phase 2. Indomethacin (Indo; 5.0 mg/kg) was used as positive control. Vehicle (DMSO),
guineensine (GN), or Indo was administered ip 30 min before formalin injection (20 μL, 1%, intraplantar). Data show mean values of at least 2
independent experiments (n = 5−16), *p < 0.05 compared to vehicle in Kruskal−Wallis test followed by Mann−Whitney U post hoc test.
Figure 3. Evaluation of guineensine in carrageenan-induced paw edema in mice. (A) Time course of paw inﬂammation, evaluated as the diﬀerences in
paw thickness. *p < 0.05 compared to vehicle using two-way ANOVA. (B) Eﬀect of guineensine on overall inﬂammation as edema over 180 min (area
under the curve). (C) Paw pain threshold, evaluated as mechanical sensitivity before and after 4 h of saline or carrageenan injection. Vehicle (DMSO) or
guineensine (GN) was administered ip 30 min before saline or carrageenan injection (50 μL, 1%, intraplantar). Data show mean values of at least 2
independent experiments (n = 5−16), *p < 0.05 compared to vehicle in Kruskal−Wallis test followed by Mann−Whitney U post hoc test.
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pain response was evaluated after 3 h of 5.0 mg/kg ip of
guineensine where it signiﬁcantly improved the pain threshold
compared to vehicle (Figure 3C). Again, there was a biphasic
inhibitory eﬀect of guineensine in the carrageenan induced
edema with 5.0 mg/kg ip being more eﬃcient than 10.0 mg/kg
ip, which may be related to multiple targets at higher doses (see
below).
Eﬀects of Guineensine in LPS-Induced Hypothermia in
BALB/c Mice.We employed an endotoxemia model measuring
acute LPS-mediated hypothermia.16 Systemic administration of
LPS (2.5 mg/kg) induced a body temperature decrease after 2 h
of injection. As shown in Figure 4A, guineensine at 5.0 and 10.0
mg/kg ip signiﬁcantly prevented this LPS-mediated hypo-
thermia. Analysis of area under the curve revealed that both
doses reduced the overall body temperature change (Figure 4B),
but when only the negative values were considered, only 5.0 mg/
kg ip had a signiﬁcant eﬀect (Figure 4C). Thus, again the lower
dose was more eﬀective than the higher dose of guineensine. We
also assessed the spontaneous motor activity in the open ﬁeld
where LPS induced a signiﬁcant reduction of active time and
distance traveled (about 40%), which was however not
modulated by guineensine treatment (Figures 4D to 4F).
Figure 4. Evaluation of guineensine in LPS-induced hypothermia in mice. (A) Time course of body temperature changes after lipopolysaccharide (LPS)
injection. *p < 0.05 compared to vehicle using two-way ANOVA. (B) Area under the curve of time-course body temperature change for total area. (C)
Area under the curve of time-course body temperature change for negative area. (D) Active time and distance traveled in the open ﬁeld test. (D)
Distance traveled in the open ﬁeld test. (F) Representative example of travel pathway in the open ﬁeld test. Vehicle (DMSO) or guineensine (GN) was
administered ip 30 min before saline or LPS injection (50 μL, 2.5 mg/kg, ip). *p < 0.05 compared with vehicle or LPS, as indicated. Data show mean
values of 3 independent experiments (n = 5−16), *p < 0.05 compared to vehicle in Kruskal−Wallis test followed by Mann−Whitney U post hoc test.
Figure 5. Evaluation of proinﬂammatory cytokines in response to guineensine and LPS-induced hypothermia in mice. (A) Interleukin 1β (IL-1β), (B)
tumor necrosis factor α (TNF-α), and (C) interleukin 6 (IL-6) were quantiﬁed in serum re-collected 2.5 h after saline or LPS injection. Values are
reported as percentage relative to group control saline + vehicle. Vehicle (DMSO) or guineensine (GN)was administered ip 30min before saline or LPS
injection (50 μL, 2.5 mg/kg, ip). *p < 0.05 compared with vehicle or LPS, as indicated. Data showmean values (n = 5−7), *p < 0.05 compared to vehicle
in Kruskal−Wallis test followed by Mann−Whitney U post hoc test.
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It has previously been shown that LPS-induced hypothermia
correlates with the release of proinﬂammatory cytokines, in
particular IL-1β, TNF-α, and IL-6.18 Here, we measured these
cytokines 2.5 h after LPS injection (ideal time point to see all
three cytokines). As shown, the LPS-induced protein production
of IL-1β (Figure 5A), TNF-α (Figure 5B), and IL-6 (Figure 5C)
in vehicle treated animals was signiﬁcantly inhibited by
guineensine when preinjected 30 min prior to LPS challenge at
5.0 and 10.0 mg/kg ip. Interestingly, for IL-1β 5.0 mg/kg ip of
guineensine was again more eﬃcient than 10.0 mg/kg ip and
even lowered the unexpected high basal IL-1β levels in these
mice (796 ± 45 pg/mL) (Figure 5A). On the other hand the
basal IL-6 levels (169 ± 45 pg/mL) were relatively low but
dramatically increased upon LPS challenge (2873± 320 pg/mL)
(Figure 5C). The high IL-1β levels could be due to the BALB/c
strain used where similar levels have been reported.19 Both doses
fully inhibited the LPS-induced TNF-α release but only partially
inhibited the expression of IL-6 (approximately 50%). Overall,
these data indicate that guineensine attenuates proinﬂammatory
cytokine production.
Diﬀerential Eﬀects of Guineensine on Extrapyramidal
Behaviors in Endotoxemia. Endotoxin challenge with LPS
produced signiﬁcant hypothermia, catalepsy, hypolocomotion,
and hyperalgesia (Figure 6). Thus, LPS triggered three out of
four behavioral phenomena that were also induced by
guineensine.6 Here, we assessed the combined eﬀects of LPS
and guineensine in these tests. As is shown in Figure 6A, 5.0 mg/
kg ip guineensine prevented the hypothermia induced by LPS.
Intriguingly, despite 5.0 mg/kg ip guineensine giving a catalepsy
in noninﬂamed mice,6 it fully abolished the catalepsy induced by
LPS (Figure 6B). However, in the locomotion experiment
(rotarod), guineensine did not antagonize the eﬀects of LPS
(Figure 6C). As expected, guineensine was analgesic and
eﬃciently inhibited the hyperalgesic eﬀects of LPS (Figure
6D). In order to get more insights into the mode of action, we
used the CB1 receptor inverse agonist/antagonist rimonabant
Figure 6. Evaluation of tetrad test in mice with LPS-induced hypothermia and guineensine treatment. (A) Change in rectal temperature. (B) Catalepsy
latency in the bar test. (C) Latency to fall in the rotarod test at 4 rpm. (D) Pain latency in the hot plate test at 55 °C. Vehicle (DMSO) or guineensine
(GN) was administered ip 60 min after lipopolysaccharide (LPS) injection (50 μL, 2.5 mg/kg, ip). Rimonabant (SR1) was administered ip 30 min
before guineensine. Data show mean values of at least 2 independent experiments (n = 5−11), *p < 0.05 compared with vehicle, LPS or SR1 + GN, as
indicated in Kruskal−Wallis test followed by Mann−Whitney U post hoc test.
Figure 7. In vitro pharmacological screening of guineensine at 10 μM. The CEREP screen was carried out over an extended CNS adverse drug-reaction
panel, which included 45 receptors, transporters, and ion channels. The threshold to excluded signiﬁcant interaction was >50% of binding/response.
The assays were performed in duplicate (N = 4). Data show mean values ± SD.
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prior to guineensine treatment. As shown in Figure 6, the
hypothermia and analgesic eﬀects of guineensine were mediated
through CB1 receptors as they could be fully blocked by
rimonabant. However, the hypolocomotion and catalepsy
presented with LPS/guineensine was apparently independent
of CB1 receptors (Figures 6B and 6C).
Pharmacological Proﬁling of Guineensine on CNS
Proteins. Since guineensine by itself induced apparent
extrapyramidal eﬀects in mice (Figure 6C) and we previously
found that the guineensine-induced hypolocomotion was only
partially mediated by CB1 receptors,6 we carried out a
pharmacological proﬁling on 45 CNS-related receptors, trans-
porters, and ion channels. Employing the CEREP platform, at 10
μM of guineensine, only few potential additional CNS targets
could be identiﬁed. Considering the commonly used threshold
binding/response of >50% at 10 μM, it was found that
guineensine was able to interact with the dopamine transporter
(DAT), sigma receptor, and 5-HT2A and 5-HT2B receptors
(Figure 7). Although no concentration-dependent assessment of
these likely molecular interactions has been carried out, the
binding interaction with 5HT2A and sigma receptors was clearly
outstanding, and these might be relevant biological targets of this
dietary N-isobutylamide.
■ DISCUSSION
The dried fruits of diﬀerent pepper species, including P. nigrum
L., P. longum L., and P. guineense Schumach, are widely used
spices. They are primarily consumed because of their pungent
taste, which is thought to be mediated by TRP and K2P
channels,5 but adaptive biological reasons like counteracting
metabolic stress induced by high-calorie diets cannot be
excluded.14 Additionally, the fruits and other plant parts of
these peppers are used ethnomedically in diﬀerent cultures for
their medicinal properties, such as antirheumatic, anti-inﬂam-
matory, antibacterial, and antifungal.20 In Asian traditional
medicine pepper species have been used for millennia and are
known to exert analgesic and anti-inﬂammatory eﬀects.21−23
Moreover, Piper nigrum L. and Piper longum L. are used
traditionally to treat psychiatric disorders like aﬀective
disorders.24,25
The N-isobutylamide guineensine was previously identiﬁed as
a potent dietary uptake inhibitor for both endocannabinoids in
vitro, increasing the extracellular levels of AEA and 2-AG in U937
and HMC-1 cells. This increase was pharmacologically
associated with cannabimimetic eﬀects in vivo in the tetrad
test.6 In agreement, increased endocannabinoid levels, for
example after inhibition of AEA or 2-AG degradation, show
pronounced anti-inﬂammatory and analgesic eﬀects in several
experimental models of inﬂammatory26−28 and neuropathic
pain.29,30 Also, some moderately selective AEA uptake/FAAH
inhibitors like AM404, OMDM-2, and UCM70731 have been
tested in inﬂammatory models of acute pain and in models of
neuropathic pain, showing anti-inﬂammatory and analgesic
eﬀects mediated by cannabinoid receptors but also by
peroxisome proliferator-activated receptors and transient
receptor potential vanilloid 1 (TRPV1).28,32−36 More recently,
the highly potent and selective endocannabinoid reuptake
inhibitor WOBE437 was shown to exert anti-inﬂammatory and
analgesic eﬀects.10
Here, pretreatment with guineensine eﬃciently prevented the
endotoxemia induced by LPS, resulting in a reduction in acute
hypothermia and expression of the proinﬂammatory cytokines
IL-1β, TNF-α, and IL-6. The endocannabinoid degradation
inhibitors JZL184 (monoacylglycerol lipase inhibitor) and
URB597 (FAAH inhibitor) were shown to decrease IL-1β in
frontal cortex, hypothalamus, and plasma after an immunological
challenge with LPS in rats,37,38 and JZL184 also decreased IL-6
and TNF-α through cannabinoid receptors.38 Furthermore, 2-
AG was shown to protect against inﬂammation induced by LPS
in a primary culture of caudate nucleus neurons, by decreasing
cyclooxygenase-2 expression through a CB1 mechanism.39
However, contrasting results have been found in rodent models
of LPS-induced hypothermia, where CB1 knockout mice or CB1
antagonism prevented the hypothermia and rather decreased
TNF-α40 and IL-6 levels.41 In other experiments, AEA or JZL184
enhanced LPS-induced hypothermia through a CB1 receptor-
dependent mechanism, but did not decrease body temperature
by themselves.40,42 These divergent results could be due to LPS
dose, administration route, mouse strain, or time point of
circadian rhythm. The general anti-inﬂammatory eﬀect of
guineensine reported here was biphasic, being more potent at
the lower concentrations, which might reﬂect diﬀerential
polypharmacology.
In our previous study, guineensine potently induced hypo-
thermia, catalepsy, hypolocomotion, and analgesia (tetrad test)
under normal physiological conditions.6While in normal animals
the analgesia and catalepsy could be inhibited fully by
rimonabant, the hypothermia and locomotion eﬀects were only
partially inhibited by CB1 receptor antagonism. In this study we
evaluated whether guineensine treatment in endotoxemic mice
showed protective eﬀects that were CB1 receptor-dependent.
The endotoxin challenge with LPS induced signiﬁcant hypo-
thermia, catalepsy, hypolocomotion, and hyperalgesia in mice, in
agreement with the literature.16,43,44 Interestingly, guineensine
potently inhibited all LPS mediated eﬀects but not the
hypolocomotion induced by LPS. In fact, the locomotion
depression may have been additive rather than antagonistic.
Moreover, guineensine reduced hypothermia and hyperalgesia
by a CB1 receptor-dependent mechanism, in agreement with its
previously reported eﬀect on endocannabinoid reuptake.6 The
hypolocomotion after LPS injection has been previously
reported being associated with sickness behavior.45,46 Because
guineensine exhibited extrapyramidal eﬀects that appeared to be
independent of CB1 receptor activation, at least partially, we
proﬁled this natural product on 45 CNS related receptors, ion
channels, and transporters. As a result, guineensine was found to
interact signiﬁcantly with the sigma and 5-HT2A receptors, as
well as DAT and the 5-HT2B receptor. Although further
biochemical analyses will be necessary to assess the potential role
of these targets for the pharmacology of guineensine, the CNS
targets identiﬁed here might explain some of the extrapyramidal
eﬀects in mice. Dopamine is known to modulate motor
coordination through direct and indirect pathways in basal
ganglia,47,48 and also 5-HT2A receptors have been reported to
increase or improve locomotor activity, particularly due to its
expression in cerebellar fastigial nucleus neurons.49,50 Sigma
receptors, mostly sigma 2, are also implicated in locomotion
because they modulate dopamine signaling.51−53 The eﬀects of
guineensine on the function of these targets should be tested in
future experiments and put into context with the overall
bioavailability of guineensine.
In summary, guineensine is a dietary endocannabinoid uptake
inhibitor that shows signiﬁcant anti-inﬂammatory properties in
vivo with associated analgesic eﬀects. The acute decrease in
locomotion, in particular under inﬂammatory conditions, might
be due to extrapyramidal eﬀects related to its aﬃnity to 5-HT2A,
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sigma receptors, and maybe DAT. In light of the abundance of
guineensine in pepper and its explicit CNS polypharmacology,
further experiments will have to address the metabolic stability
and oral bioavailability of this dietary phytochemical and its likely
role as a pharmacologically active natural product. Overall, the
here reported bioactivity of guineensine might be associated with
the reported anti-inﬂammatory eﬀects and general health claims
of dietary pepper.
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